Clinical Trial Update: Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India [Phase 4]

View source ↗

Summary

Phase 4 trial update of Nirsevimab for RSV immunization in children up to 24 months in India; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Nirsevimab (nirsevimab)

Snippet

Sponsor: Sanofi | Conditions: RSV Immunization | Phase 4 | Status: ACTIVE_NOT_RECRUITING